Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 12164 pages

Showing 151 - 200


hematologic malignancies
genomics/genetics

Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?

Jyoti Nangalia, MBBChir, of Wellcome Sanger Institute and the University of Cambridge, discusses how her team used large-scale whole-genome sequencing to precisely time the origins of a blood cancer­­­­­ and measure how it grew. The information could provide opportunities for early diagnosis and...

multiple myeloma
immunotherapy

Sagar Lonial, MD, on CAR T-Cell Therapies for Myeloma: Novel Approaches and Longer-Term Follow-up Data

Sagar Lonial, MD, of the Emory University School of Medicine, summarizes key papers presented in a session he co-moderated on how second-generation CAR T cells can be used to treat patients with multiple myeloma (Session 653).

leukemia
myelodysplastic syndromes

ASH 2020: Role of Venetoclax in High-Risk Myeloid Malignancies

The BCL2 inhibitor venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers, and in early studies, the combination showed improved outcomes, according to two reports presented by Jacqueline S. Garcia, MD, and colleagues at the 2020 American Society of Hematology ...

multiple myeloma
immunotherapy

ASH 2020: Subcutaneous Teclistamab for Relapsed or Refractory Multiple Myeloma Studied in Phase I Trial

A subcutaneous injection of the BCMAxCD3 bispecific antibody teclistamab was found to be safe and elicited responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study presented by Alfred L. Garfall, MD, and...

hematologic malignancies
covid-19

ASH 2020: Environmental Surface Testing for Presence of SARS-CoV-2 in Inpatient and Outpatient Hematology/Oncology Settings

A research team from Rutgers Cancer Institute of New Jersey evaluated the presence of SARS-CoV-2 on various environmental surfaces in outpatient and inpatient hematology/oncology settings. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient...

leukemia

Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy

Curtis Lachowiez, MD, of The University of Texas MD Anderson Cancer Center, discusses an interim analysis of a phase Ib/II study showing that venetoclax plus chemotherapy represents an effective regimen, particularly in patients with newly diagnosed and relapsed or refractory acute myeloid...

Mohandas Narla, DSc, Receives 2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology

The American Society of Hematology (ASH) presented Mohandas Narla, DSc, of the New York Blood Center, with the 2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Narla is being recognized for his significant contributions to hematology through his groundbreaking research, his ...

2020 Ernest Beutler Lecture and Prize Presented to Ari Melnick, MD, and Courtney DiNardo, MD

The American Society of Hematology (ASH) will honor Ari Melnick, MD, of Weill Cornell Medicine in New York, and ­Courtney DiNardo, MD, of the University of Texas MD Anderson Cancer Center, with the 2020 Ernest Beutler Lecture and Prize for their significant research contributions to the treatment...

leukemia

ASH 2020: Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia

A phase I/II study found that IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but aggressive form of leukemia. Treatment with the...

hematologic malignancies

ASH 2020: Clonal Hematopoiesis in Donors Aged 40 and Older May Be Linked to Improved Survival in Stem Cell Transplant Recipients

A study presented by Christopher Gibson, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 80) has revealed for the first time that clonal hematopoiesis may confer a health benefit in allogeneic stem cell or bone marrow transplants....

lymphoma
immunotherapy

ASH 2020: Early Research Shows CD58 May Be a Biomarker for Response to Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma

Although the immunotherapy axicabtagene ciloleucel has significantly improved treatment outcomes for some patients with large B-cell lymphoma, not all patients benefit.  In a new study presented by Robbie G. Majzner, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting ...

hematologic malignancies
issues in oncology

Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors

Smita Bhatia, MD, MPH, and Radhika Gangaraju, MD, both of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discuss findings that showed survivors of bone marrow transplants are at a 7- to 12-fold higher risk of coronary heart disease than a sibling comparison ...

lymphoma

Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP

Emmanuel Bachy, MD, PhD, of the Hospices Civils de Lyon, discusses the final analysis of a phase III study of adding romidepsin to chemotherapy in patients with previously untreated peripheral T-cell lymphoma. Adding romidepsin did not improve progression-free survival and was associated with high...

myelodysplastic syndromes

Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease

Corey Cutler, MD, MPH, of Dana-Farber Cancer Institute, discusses results from a multicenter trial that compared reduced-intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50 to 75 with advanced myelodysplastic syndromes...

covid-19
immunotherapy

ASH 2020: SARS-Cov-2 Multivirus-Specific T Cells for the Treatment of Hospitalized Patients With COVID-19

Researchers have successfully built banks of SARS-CoV-2–specific T cells obtained from people who recovered from the virus that are now poised to be used as an experimental treatment in patients hospitalized with COVID-19. This T cell–based therapy may represent a step forward in the search for...

issues in oncology
leukemia

Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes

Ann-Kathrin Eisfeld, MD, of The Ohio State University Comprehensive Cancer Center, discusses SEER data showing that patients with acute myeloid leukemia who are Black and younger than age 60 may have poor survival outcomes, a disparity that should be addressed and further studied to establish...

hematologic malignancies
symptom management

ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies

The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophylactic platelet transfusions, according to findings presented by Terry B. Gernsheimer, MD, and...

prostate cancer
genomics/genetics

Study Shows Regional Variation in Genomic Testing for Men With Prostate Cancer

A study published by Michael S. Leapman, MD, and colleagues in JAMA Oncology found substantial regional variation in the use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies. “Little was known...

lymphoma
leukemia
hepatobiliary cancer
symptom management
lung cancer
immunotherapy

FDA Pipeline: Agents in DLBCL, SCLC, AML, and More

Recently, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions for agents to treat diffuse large B-cell lymphoma (DLBCL), small cell lung cancer (SCLC), acute myeloid leukemia (AML), biliary tract cancer, and graft-vs-host disease. Priority Review for Loncastuximab Tesirine...

gynecologic cancers
immunotherapy

Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab

Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free...

issues in oncology
survivorship

Social Needs May Be Linked to Low Health-Related Quality of Life Among Black Cancer Survivors

Social needs—such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation—were common in a group of Black cancer survivors in Detroit. These factors were associated with lower health-related quality of life, according to findings published by...

thyroid cancer

FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

On December 1, the U.S. Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, or for patients with RET fusion–positive thyroid cancer...

prostate cancer

FDA Approves Gallium-68 PSMA-11 for PSMA-Targeted PET Imaging in Prostate Cancer

On December 1, the U.S. Food and Drug Administration (FDA) approved gallium-68 PSMA-11—the first drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Gallium-68 PSMA-11 is indicated for patients with suspected ...

head and neck cancer
immunotherapy

Phase II Study of Combination Immunotherapy for Advanced Nasopharyngeal Cancer

Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated efficacy and safety findings from a phase II study presented by Kao et al at ESMO Asia Virtual Congress 2020 (Abstract 266O)....

cns cancers
immunotherapy

Does Concurrent Treatment With Dexamethasone Diminish the Efficacy of Immune Checkpoint Inhibitors in Patients With Glioblastoma?

Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published by Iorgulescu et al in Clinical Cancer Research....

covid-19

FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for December 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc. “In keeping with the FDA’s commitment ...

colorectal cancer

ESMO Asia 2020: Performance of Immunoscore in Asian Patients With Early-Stage Colon Cancer

The Immunoscore assay can assess the risk of disease recurrence in Asian patients with early-stage colon cancer and may be used together with TNM classification to guide clinical decision-making, according to findings presented at the European Society for Medical Oncology (ESMO) Asia Virtual...

solid tumors
immunotherapy

FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk...

ELNEC Project Reaches Historic Milestone in End-of-Life Care

The End-of-Life Nursing Education Consortium (ELNEC) project is ending 2020 by surpassing a goal established 20 years ago, reporting more than 1 million nurses and other professionals trained using the ELNEC curriculum. Administered through a partnership between the American Association of Colleges ...

Rogel Team at University of Michigan Receives $11.2M to Leverage the Microbiome Against Graft-vs-Host Disease

A team of researchers from the University of Michigan Rogel Cancer Center in Ann Arbor received an $11.2 million grant from the National Heart, Lung, and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases....

colorectal cancer

U.S. Multisociety Task Force on Colorectal Cancer Offers Management Strategies for Malignant Colorectal Polyps

Early identification and removal of cancerous colorectal polyps are critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for...

Global Cancer Institute Extends Programs to Bangladesh for Underserved Patients With Cancer

Global Cancer Institute (GCI), which is focused on improving survival rates for underserved patients with cancer worldwide, recently announced it has extended its programs to Bangladesh. The extension begins with the launch of monthly tumor boards, which help physicians and oncologists in...

skin cancer

Expect Questions About Mohs Micrographic Surgery

A recent study finding similar overall survival rates for patients with melanomas of the trunk and extremities treated with Mohs micrographic surgery or wide local excision1 raises questions about why and when physicians might recommend, and patients opt for, one or the other procedure. “The most...

skin cancer

Mohs Surgery vs Wide Local Excision for Trunk and Extremity Melanomas: Comparable Overall Survival Rates

A cohort study of 188,862 cases of all-stage melanomas of the trunk and extremities found no differences in overall survival between patients treated with Mohs micrographic surgery or with wide local excision.1 “These findings add to the existing body of evidence demonstrating that wide local...

breast cancer

Yes, Men Get Breast Cancer, Too

You could call it a sixth sense, but the moment I felt a lump in my left breast I knew it was cancer, although it would take several weeks to confirm the diagnosis. When I saw my primary cancer physician and told him of my concern, he said: “Don’t worry. Men don’t get breast cancer; it’s a woman’s...

Penn Medicine Researchers Receive $5.4 Million Grant to Find Genetic Drivers of Testicular Cancer

The international hunt to find more genetic risk markers for testicular cancer is expanding. A team of researchers led by Katherine L. Nathanson, MD, Deputy Director of the Abramson Cancer Center and the Pearl Basser Professor for BRCA-Related Research in the Perelman School of Medicine at the...

SIO and ASCO Collaborate to Develop Evidence-Based Guidelines for Integrative Therapies for Oncology

The Society for Integrative Oncology (SIO) has announced its collaboration with ASCO in the development of a series of evidence-based clinical practice guidelines for integrative therapies in oncology care. The guidelines, planned for publication in 2021 and 2022, will provide clinicians and...

Mount Sinai Receives $4 Million Gift to Support Prostate Health and Urology Department

Mount Sinai has received a $4 million donation from Lizzie and Jonathan Tisch to support prostate health and the Milton and Carroll Petrie Department of Urology at Mount Sinai. The prostate program—founded by Ash Tewari, MBBS, MCh, Kyung Hyun Kim, MD Professor and Chair of Urology—will be named the ...

South Florida Cancer Experts Make the Move to Sylvester

Four experienced oncologists who have been treating patients with cancer in South Florida for many years are joining Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and the region’s only cancer center to achieve a National Cancer Institute (NCI) designation....

FDA Offers Guidance to Enhance Diversity in Clinical Trials, Encourage Inclusivity in Medical Product Development

Stephen M. Hahn, MD, Commissioner at the U.S. Food and Drug Administration (FDA), recently issued a statement regarding an important step that researchers and medical product sponsors can take to make sure clinical trials for medical products are more inclusive of multiple populations. “We have...

health-care policy

Medicaid Expansion May Be Linked to Lower Mortality Rates for Three Major Types of Cancer

In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major types of cancer are significantly lower than in states that have not expanded Medicaid availability, according to a recent study by researchers at Dana-Farber Cancer...

The US Oncology Network Welcomes Two More Practices

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities by welcoming Alliance Cancer Specialists and Northwest Oncology. The addition of these two independent and...

Ola Landgren, MD, PhD, Joins Sylvester Comprehensive Cancer Center at University of Miami

Hematologic oncologist Ola Landgren, MD, PhD, was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Dr. Landgren, who was Chief of...

ACS Cancer Action Network Issues New Recommendations to Increase Access to Cancer Biomarker Testing

The American Cancer Society (ACS) Cancer Action Network has released new policy recommendations to increase the uptake of biomarker testing and to advance the use of precision medicine in cancer care. A recent report by the ACS Cancer Action Network and the LUNGevity Foundation found that although...

HCI Researcher Receives Awards for Community Contributions and Neuroendocrine Tumor Research

Heloisa Soares, MD, PhD, gastrointestinal and neuroendocrine tumor medical oncologist and researcher at Huntsman Cancer Institute (HCI) and Assistant Professor of Internal Medicine at the University of Utah, received two awards from external organizations honoring her contributions to the field of...

lung cancer
issues in oncology

Racial Disparities in Treatment of Common Lung Cancer Persist Despite Gains

Lung cancer continues to be the most deadly solid cancer in the world, despite the fact that survival rates have been improving over the past decade. However, Black patients have worse outcomes and shorter lifespans after being diagnosed with lung cancer. A study published in the Journal of...

UT Austin and MD Anderson Announce First Collaborative Projects in Improving Cancer Outcomes

The University of Texas (UT) MD Anderson Cancer Center, UT Austin Oden Institute for Computational Engineering and Sciences, and UT Austin Texas Advanced Computing Center (TACC) launched a new collaboration in oncologic data and computational science earlier this year. The strategic initiative...

Rutgers Awarded $1.5 Million FEMA Grant to Support Volunteer Firefighter Cancer Research and Prevention

The Rutgers School of Public Health has received a $1.5 million Federal Emergency Management Agency (FEMA) grant to support volunteer firefighter cancer research. This grant will enhance the research currently underway in collaboration with Rutgers Cancer Institute of New Jersey, which is geared...

issues in oncology

Understanding the Uniqueness of Cancer and Survival in Adolescents and Young Adults

Numerous studies over the past 4 decades have chronicled the lack of progress in improved outcomes for adolescents and young adults (AYAs)—defined by the National Cancer Institute as those ranging in age from 15 to 39—diagnosed with cancer compared with children and older adults diagnosed with the...

MD Anderson Partners With Investment Fund to Generate Support for Investigational Therapies

In partnership with The University of Texas MD Anderson Cancer Center, The Focus Fund GP, LLC, has launched the “Cancer Focus Fund,” to provide investment support to investigational therapies in late preclinical development through to phase I and phase IB/II clinical trials. Along with the fund’s...

Advertisement

Advertisement



Advertisement